Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Feb 15, 2024 (3 years ago)

Methocarbamol Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Methocarbamol Injection, USP 1000mg/10mL, (100mg/mL), 10 mL Single-Dose Vial packed 25 vials per carton, Rx Only, Mfd. in India for: Eugia US LLC. E. Windsor, NJ 08520, NDC 55150-223-10

Affected NDC 55150-0223-10

Compare with the code on your package — it is the most precise check available.

Drug: Methocarbamol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Methocarbamol
NDC 55150-0223
1000 mg/10mL Injection, Solution
Intramuscular|intravenous
Eugia US LLC Rx
Recalling firm
Eugia US LLC
NDC code
55150-223-10
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Mar 28, 2024 · FDA notice with lot numbers
FDA recall number
D-0440-2024 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Methocarbamol recalls

See all
Class I · High risk

Methocarbamol 500mg Tablet

Labeling: Label Error on Declared Strength; Bottles labeled as Methocarbamol 500 mg Tablets actually contain Methocarbamol 750 mg Tablets

Completed Labeling / mix-up Bryant Ranch Prepack, Inc. dba BRP Pharmaceuticals D-0092-2022
Class I · High risk

robaxin-750

Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019

Other recalls by Eugia US LLC

All 2024 recalls
Class III · Low risk

Lidocaine HCl Injection

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Eugia US LLC D-0552-2026
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025